The stock of Quotient Ltd (QTNT) formed a down wedge with $5.58 target or 8.00% below today’s $6.06 share price. The 9 months wedge indicates high risk for the $177.35M company. If the $5.58 price target is reached, the company will be worth $14.19 million less.
Falling wedges are poor performers for bullish breakouts and are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 11% and 15%. The average rise is 32% and the decline is 15%. The falling wedges has high throwback and pullback rate: 56%, 69% and the percent of wedges meeting target is not very high. About 35,191 shares traded hands. Quotient Ltd (NASDAQ:QTNT) has declined 31.89% since June 7, 2016 and is downtrending. It has underperformed by 39.32% the S&P500.
Analysts await Quotient Ltd (NASDAQ:QTNT) to report earnings on February, 13. They expect $-0.62 earnings per share, up 7.46% or $0.05 from last year’s $-0.67 per share. After $-0.62 actual earnings per share reported by Quotient Ltd for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
Quotient Ltd (NASDAQ:QTNT) Ratings Coverage
Out of 2 analysts covering Quotient (NASDAQ:QTNT), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Quotient has been the topic of 3 analyst reports since August 11, 2015 according to StockzIntelligence Inc. As per Tuesday, August 11, the company rating was initiated by Jefferies. UBS maintained the stock with “Buy” rating in Wednesday, November 4 report. Zacks upgraded Quotient Ltd (NASDAQ:QTNT) rating on Friday, August 14. Zacks has “Hold” rating and $18 price target.
According to Zacks Investment Research, “Quotient Limited is a commercial-stage transfusion diagnostics company. It is focused on supplying blood-grouping consumables and developing MosaiQ, a fully automated platform for use in donor centers and patient-testing sites. Quotient Limited is headquartered in Edinburgh, Scotland and Newton, Pennsylvania.”
Insitutional Activity: The institutional sentiment increased to 2.43 in Q3 2016. Its up 1.32, from 1.11 in 2016Q2. The ratio improved, as 3 funds sold all Quotient Ltd shares owned while 4 reduced positions. 6 funds bought stakes while 11 increased positions. They now own 13.39 million shares or 10.92% more from 12.07 million shares in 2016Q2.
Blackrock Advsr Lc accumulated 693,593 shares or 0.01% of the stock. Moreover, Lpl Financial Lc has 0% invested in Quotient Ltd (NASDAQ:QTNT) for 11,266 shares. Fny Managed Accounts last reported 15,000 shares in the company. Ghost Tree Capital Ltd accumulated 0.08% or 60,000 shares. Blackrock Gp last reported 283,423 shares in the company. Renaissance Ltd has 0% invested in the company for 22,200 shares. Cormorant Asset Management Lc has invested 2.4% of its portfolio in Quotient Ltd (NASDAQ:QTNT). Blackrock Invest Management Ltd holds 88,308 shares or 0% of its portfolio. Thompson Davis Incorporated last reported 250 shares in the company. The New York-based Perceptive Advsrs Llc has invested 1.35% in Quotient Ltd (NASDAQ:QTNT). Sio Mngmt Llc holds 11.79% of its portfolio in Quotient Ltd (NASDAQ:QTNT) for 2.19M shares. The New York-based Boothbay Fund Mngmt Limited Liability Corporation has invested 0.03% in Quotient Ltd (NASDAQ:QTNT). Morgan Stanley owns 564,713 shares or 0% of their US portfolio. First Ny last reported 0% of its portfolio in the stock. Clearbridge Ltd Liability Com accumulated 0.19% or 1.26M shares.
Insider Transactions: Since August 3, 2016, the stock had 5 insider purchases, and 0 sales for $3.47 million net activity. Shares for $250,003 were bought by COWAN D J PAUL E. $990,000 worth of Quotient Ltd (NASDAQ:QTNT) was bought by SHROFF ZUBEEN on Wednesday, August 3. On Wednesday, August 3 Cowan Deidre bought $250,003 worth of the stock or 45,455 shares. WILKERSON L JOHN bought 180,000 shares worth $990,000. $990,000 worth of Quotient Ltd (NASDAQ:QTNT) shares were bought by Galen Partners V LP.
QTNT Company Profile
Quotient Limited, incorporated on January 18, 2012, is a diagnostics company. The Firm focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market. It is engaged in developing MosaiQ, which is its technology platform. MosaiQ consists of approximately two consumables, which include a consumable for blood grouping and a consumable for serological disease screening, and a high-throughput instrument. The Firm is also engaged in developing a third consumable for molecular disease screening. The Company’s MosaiQ offers a breadth of diagnostic tests.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.